The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

PURPOSE: mTOR pathway hyperactivation occurs in nearly 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here we examine the efficacy of the newly discovered ATP-competitive mTOR kinase inhibitors CC214-1 and CC214-2 in glioblastoma, identifying molecular de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gini, Beatrice, Zanca, Ciro, Guo, Deliang, Matsutani, Tomoo, Masui, Kenta, Ikegami, Shiro, Yang, Huijun, Nathanson, David, Villa, Genaro R., Shackelford, David, Zhu, Shaojun, Tanaka, Kazuhiro, Babic, Ivan, Akhavan, David, Lin, Kelly, Assuncao, Alvaro, Gu, Yuchao, Bonetti, Bruno, Mortensen, Deborah S., Xu, Shuichan, Raymon, Heather K., Cavenee, Webster K., Furnari, Frank B, James, David, Kroemer, Guido, Heath, James, Hege, Kristen, Chopra, Rajesh, Cloughesy, Timothy, Mischel, Paul S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815450/
https://ncbi.nlm.nih.gov/pubmed/24030701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0527
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados